ProCE Banner Activity

Phase I Study of IMGN779, a Novel CD33-Targeted ADC, in Relapsed/Refractory CD33+ Acute Myeloid Leukemia

Slideset Download
Conference Coverage
Investigational anti-CD33 antibody–drug conjugate with a novel mechanism of action demonstrated preliminary antileukemia activity and tolerability in dose-escalation study.

Released: December 03, 2018

Expiration: December 02, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology